Table 2.

HRs and 95% confidence intervals (CI) for all-cause in relation to tumor composite scores for CTLs and GZMB in the colorectal cancer patients, IWHS, 1986–2011

All-cause death
Composite scoreNo. of deathsbPerson-yearsHR (95% CI)cHR (95% CI)dHR (95% CI)eHR (95% CI)f
CTLan = 313
2–3.976745ReferenceReferenceReferenceReference
4–5.11001,0890.92 (0.68–1.23)0.72 (0.53–0.99)0.75 (0.54–1.05)0.74 (0.54–1.01)
5.2–6.3721,0400.69 (0.50–0.96)0.68 (0.49–0.95)0.67 (0.46–0.98)0.76 (0.53–1.07)
>6.3651,0170.64 (0.46–0.90)0.53 (0.38–0.75)0.49 (0.32–0.73)0.62 (0.41–0.94)
Ptrend0.0020.00040.00060.04
GZMBan = 310
21461,518ReferenceReferenceReferenceReference
2.2–2.81007440.81 (0.59–1.09)0.82 (0.60–1.12)0.76 (0.54–1.07)0.84 (0.61–1.15)
>3641,5440.72 (0.56–0.92)0.66 (0.51–0.86)0.64 (0.46–0.89)0.78 (0.56–1.09)
Ptrend0.0090.0020.010.12
Joint score for CTLs and GZMBgn = 309
056500ReferenceReferenceReference
11992,4430.74 (0.55–1.00)0.70 (0.52–0.98)0.71 (0.51–0.99)
2548250.60 (0.41–0.87)0.50 (0.34–0.73)0.47 (0.30–0.74)
Ptrend<0.0001<0.00010.001
  • aTumor CTL and GZMB composite scores were created as a sum of corresponding epithelial and stromal scores categorized into quartiles for CTL and tertiles for GZMB.

  • bThe number of deaths is slightly different in the analyses of CTL and GZMB because of different number of available cores (n = 465 for CTL and n = 458 for GZMB; overall 468 CRC patients had tissues immunostained for CTL or GZMB).

  • cModel 1: Unadjusted.

  • dModel 2: Model adjusted for age at diagnosis, BMI, smoking status, stage, and grade at diagnosis.

  • eModel 3: Model 2 + integrated pathway.

  • fBoth GZMB and CTL tumor composite scores were included in addition to all the variables in Model 2.

  • gJoint score for GZMB and CTL tumor composite scores was created as follows: 0, lowest categories of CTL and GZMB; 2, highest categories of CTL and GZMB; and 1, all other combinations.